Latest & greatest articles for budesonide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on budesonide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on budesonide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for budesonide

1. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study Full Text available with Trip Pro

Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Am J Respir Crit Care Med Actions . 2021 Mar 1;203(5):553-564. doi: 10.1164/rccm.202006-2618OC. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary

2021 EvidenceUpdates

2. Formoterol fumarate dihydrate/glycopyrronium/budesonide (Trixeo Aerosphere) - adult patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Formoterol fumarate dihydrate/glycopyrronium/budesonide (Trixeo Aerosphere) - adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) Published 08 February 2021 1 Product update SMC2321 formoterol fumarate dihydrate / glycopyrronium / budesonide 5mcg/7.2mcg/160mcg pressurised inhalation, suspension (Trixeo® Aerosphere) AstraZeneca 15 January 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC (...) executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission formoterol fumarate dihydrate / glycopyrronium / budesonide (Trixeo® Aerosphere) is accepted for restricted use within NHSScotland. Indication under review: maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination

2021 Scottish Medicines Consortium

3. Formoterol / glycopyrronium bromide / budesonide (Trixeo Aerosphere) - chronic obstructive pulmonary disease (COPD)

Formoterol / glycopyrronium bromide / budesonide (Trixeo Aerosphere) - chronic obstructive pulmonary disease (COPD) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/561272/2020 (...) EMEA/H/C/004983 Trixeo Aerosphere (formoterol / glycopyrronium bromide / budesonide) An overview of Trixeo Aerosphere and why it is authorised in the EU What is Trixeo Aerosphere and what is it used for? Trixeo Aerosphere is a medicine used to treat patients with moderate to severe chronic obstructive pulmonary disease (COPD), a long-term disease in which the airways and air sacs in the lungs become damaged or blocked, leading to difficulty breathing. Trixeo Aerosphere is used for maintenance

2021 European Medicines Agency - EPARs

4. Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis Full Text available with Trip Pro

Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) : 10.1053/j.gastro.2020.07.039. Epub 2020 Jul 25. Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators International EOS-2 Study Group : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations 1 Swiss Eosinophilic Esophagitis Research Group, Olten, Switzerland; Department of Gastroenterology and Hepatology

2020 EvidenceUpdates

5. Budesonide (Jorveza) - Treatment of eosinophilic oesophagitis (EoE)

Budesonide (Jorveza) - Treatment of eosinophilic oesophagitis (EoE) 1 Published 12 October 2020 1 SMC2158 budesonide 1mg orodispersible tablets (Jorveza®) Dr Falk Pharma UK Ltd 04 September 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission (...) budesonide (Jorveza®) is accepted for restricted use within NHSScotland. Indication under review: Treatment of eosinophilic oesophagitis (EoE) in adults (older than 18 years of age). SMC restriction: For patients unsuccessfully treated with proton pump inhibitors. One randomised, double-blind phase III study, demonstrated superiority of budesonide over placebo in inducing clinico-histologic remission in adult patients with EoE, refractory to treatment with a proton pump inhibitor. The case presented

2020 Scottish Medicines Consortium

6. Budesonide (Jorveza) - maintenance therapy for eosinophilic esophagitis

Budesonide (Jorveza) - maintenance therapy for eosinophilic esophagitis budesonide (Jorveza®) - All Wales Medicines Strategy Group Opens in new window Cymraeg Search Search Cymraeg Menu Search › › › budesonide (Jorveza®) Following non-submission AWMSG advice Status: Not endorsed (Statement of Advice) In the absence of a submission from the holder of the marketing authorisation, budesonide (Jorveza®) cannot be endorsed for use within NHS Wales as maintenance therapy for eosinophilic esophagitis (...) in adults (older than 18 years of age). Medicine details Medicine name budesonide (Jorveza®) Formulation 0.5 mg and 1 mg orodispersible tablet Reference number 4507 Indication As maintenance therapy for eosinophilic esophagitis in adults (older than 18 years of age) Company Dr Falk Pharma UK Ltd BNF chapter Gastro-intestinal system Submission type Non-submission Status Not endorsed (Statement of Advice) Date of issue 24/09/2020 Built by

2020 All Wales Medicines Strategy Group

7. Nasal nebulization inhalation of budesonide for chronic rhinosinusitis with nasal polyps: A protocol for systematic review and meta-analysis Full Text available with Trip Pro

Nasal nebulization inhalation of budesonide for chronic rhinosinusitis with nasal polyps: A protocol for systematic review and meta-analysis Inplasy Protocol 130 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review Protocols

8. Budesonide / formoterol fumarate dihydrate - asthma

Budesonide / formoterol fumarate dihydrate - asthma Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/118969/2020 EMEA/H/C/004882 Budesonide/Formoterol Teva Pharma B.V (...) . (budesonide/ formoterol) An overview of Budesonide/Formoterol Teva Pharma B.V. and why it is authorised in the EU What is Budesonide/Formoterol Teva Pharma B.V. and what is it used for? Budesonide/Formoterol Teva Pharma B.V. is a medicine used for the treatment of asthma in adults for whom a combination product is considered appropriate. It can be used in patients: • whose disease is not adequately controlled by treatment with other asthma medicines called corticosteroids and ‘short-acting beta-2 agonists

2020 European Medicines Agency - EPARs

9. Effect of airway administration of budesonide for bronchopulmonary dysplasia in premature infants: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

Effect of airway administration of budesonide for bronchopulmonary dysplasia in premature infants: A Systematic Review and Meta-Analysis Effect of airway administration of budesonide for bronchopulmonary dysplasia in premature infants: A Systematic Review and Meta-Analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting (...) preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Effect of airway administration of budesonide for bronchopulmonary dysplasia in premature infants: A Systematic Review and Meta-Analysis kaixu wang, Long Chen, Fang Li kaixu wang Children's hospital of Chongqing Medical University ORCiD: https://orcid.org/0000-0001-5459-3727 Long Chen

2019 Research Square

10. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. (Abstract)

Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. In adults with mild asthma, a combination of an inhaled corticosteroid with a fast-onset long-acting β-agonist (LABA) used as reliever monotherapy reduces severe exacerbations compared with short-acting β-agonist (SABA) reliever therapy. We investigated the efficacy (...) of combination budesonide-formoterol reliever therapy compared with maintenance budesonide plus as-needed terbutaline.We did a 52-week, open-label, parallel-group, multicentre, superiority, randomised controlled trial at 15 primary care or hospital-based clinical trials units and primary care practices in New Zealand. Participants were adults aged 18-75 years with a self-reported doctor's diagnosis of asthma who were using SABA for symptom relief with or without maintenance low to moderate doses of inhaled

2019 Lancet Controlled trial quality: predicted high

11. Meta-analysis of the efficacy of pulmonary surfactants combined with budesonide for the prevention of bronchopulmonary dysplasia Full Text available with Trip Pro

Meta-analysis of the efficacy of pulmonary surfactants combined with budesonide for the prevention of bronchopulmonary dysplasia Meta-analysis of the efficacy of pulmonary surfactants combined with budesonide for the prevention of bronchopulmonary dysplasia | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints (...) . The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Meta-analysis of the efficacy of pulmonary surfactants combined with budesonide for the prevention of bronchopulmonary dysplasia Bingbin He, Jiayong Zhuang, Boran Ye, Guosheng Liu Bingbin He Department of pediatric Jiayong Zhuang Department of pediatric, The sixth hospital of huizhou Boran Ye

2019 Research Square

12. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial Full Text available with Trip Pro

Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial Topical steroid treatments for eosinophilic esophagitis (EoE) include swallowed fluticasone from a multi-dose inhaler (MDI) or oral viscous budesonide (OVB) slurry, but the 2 have never been compared. We assessed whether OVB was more effective than MDI for initial treatment of patients with EoE.In a double-blind, double-dummy trial, patients with a new diagnosis of EoE were

2019 EvidenceUpdates

13. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial Full Text available with Trip Pro

Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial Swallowed topical-acting corticosteroids are recommended as first-line therapy for eosinophilic esophagitis (EoE). Asthma medications not optimized for esophageal delivery are sometimes effective, although given off-label. We performed a randomized, placebo-controlled trial to assess the effectiveness and tolerability of a budesonide orodispersible tablet (BOT (...) had achieved remission. Six-week and 12-week BOT administration were safe and well tolerated; 5% of patients who received BOT developed symptomatic, mild candida, which was easily treated with an oral antifungal agent.In a randomized trial of adults with active EoE, we found that budesonide oral tablets were significantly more effective than placebo in inducing clinical and histologic remission. Eudra-CT number 2014-001485-99; ClinicalTrials.gov ID NCT02434029.Copyright © 2019 AGA Institute

2019 EvidenceUpdates

14. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. Full Text available with Trip Pro

Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. In double-blind, placebo-controlled trials, budesonide-formoterol used on an as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed use of a short-acting β2-agonist (SABA); the risk was similar to that of budesonide maintenance therapy plus as-needed SABA. The availability of data from clinical trials designed to better reflect clinical practice would be beneficial.We conducted a 52-week (...) , randomized, open-label, parallel-group, controlled trial involving adults with mild asthma. Patients were randomly assigned to one of three treatment groups: albuterol (100 μg, two inhalations from a pressurized metered-dose inhaler as needed for asthma symptoms) (albuterol group); budesonide (200 μg, one inhalation through a Turbuhaler twice daily) plus as-needed albuterol (budesonide maintenance group); or budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol, one inhalation through

2019 NEJM Controlled trial quality: predicted high

15. Effects of Budesonide Combined with Noninvasive Ventilation on PCT, sTREM-1, Chest Lung Compliance, Humoral Immune Function and Quality of Life in Patients with AECOPD Complicated with Type II Respiratory Failure. Full Text available with Trip Pro

Effects of Budesonide Combined with Noninvasive Ventilation on PCT, sTREM-1, Chest Lung Compliance, Humoral Immune Function and Quality of Life in Patients with AECOPD Complicated with Type II Respiratory Failure. Our objective is to explore the effects of budesonide combined with noninvasive ventilation on procalcitonin (PCT), soluble myeloid cell triggering receptor-1 (sTREM-1), thoracic and lung compliance, humoral immune function, and quality of life in patients with acute exacerbation (...) of chronic obstructive pulmonary disease (AECOPD) complicated with type II respiratory failure.There were 82 patients with AECOPD complicated with type II respiratory failure admitted into our hospital between March, 2016-September, 2017. They were selected and randomly divided into observation group (n=41) and control group (n=41). The patients in the control group received noninvasive mechanical ventilation and the patients in the observation group received budesonide based on the control group

2019 Open medicine (Warsaw, Poland) Controlled trial quality: uncertain

16. Effect of preoperative inhaled budesonide on pulmonary injury after cardiopulmonary bypass: A randomized pilot study Full Text available with Trip Pro

Effect of preoperative inhaled budesonide on pulmonary injury after cardiopulmonary bypass: A randomized pilot study Cardiopulmonary bypass can result in lung injury. This prospective, double-blinded, randomized trial aimed to evaluate the protective effect of inhaled budesonide on lung injury after cardiopulmonary bypass.Sixty patients, aged 25 to 65 years, requiring cardiopulmonary bypass were randomized to groups treated with saline or budesonide inhalation preoperatively. The respiratory (...) mechanics after cardiopulmonary bypass. Budesonide improved the partial pressure of arterial oxygen to the fraction of inspired oxygen ratio from 8 to 48 hours after the operation. Budesonide shortened the durations of mechanical ventilation and postoperative recovery time. Budesonide decreased the levels of proinflammatory factors while increasing the levels of anti-inflammatory factors in bronchoalveolar lavage fluid and serum (all P < .05). The macrophage and neutrophil counts, and protein

2018 EvidenceUpdates

17. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study Full Text available with Trip Pro

Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study TELOS compared budesonide (BD)/formoterol fumarate dihydrate (FF) metered dose inhaler (BFF MDI), formulated using innovative co-suspension delivery technology that enables consistent aerosol performance, with its monocomponents and budesonide/formoterol fumarate dihydrate dry powder inhaler (DPI) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), without a requirement (...) for an exacerbation history.In this phase III, double-blind, parallel-group, 24-week study (NCT02766608), patients were randomised to BFF MDI 320/10 µg (n=664), BFF MDI 160/10 µg (n=649), FF MDI 10 µg (n=648), BD MDI 320 µg (n=209) or open-label budesonide/formoterol DPI 400/12 µg (n=219). Primary end-points were change from baseline in morning pre-dose trough forced expiratory volume in 1 s (FEV1) and FEV1 area under the curve from 0-4 h (AUC0-4). Time to first and rate of moderate/severe exacerbations were

2018 EvidenceUpdates

18. Budesonide

aspiration: randomized controlled trial. A total of 78 neonates were included in the study. After randomization, intervention group received nebulization with Budesonide (0.5 mg dissolved 2014 17. Pulmicort Respules( Budesonide Inhalation Suspension) vs Singulair, Children Pulmicort Respules( Budesonide Inhalation Suspension) vs Singulair, Children - Full Text View - ClinicalTrials.gov A service of the U.S. National Institutes of Health Example: "Heart attack" AND "Los Angeles" Search for studies: Study (...) Record Detail Pulmicort Respules( Budesonide Inhalation Suspension) vs Singulair, Children This study has been completed. Sponsor: AstraZeneca Information provided by: AstraZeneca (...) will receive 5mg strength SINGULAR. Asthma Drug: Budesonide inhalation suspension Drug: Montelukast Sodium Phase 4 Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment Official Title: An Evaluation of the Effectiveness

2018 Trip Latest and Greatest

19. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. (Abstract)

As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. Patients with mild asthma often rely on inhaled short-acting β2-agonists for symptom relief and have poor adherence to maintenance therapy. Another approach might be for patients to receive a fast-acting reliever plus an inhaled glucocorticoid component on an as-needed basis to address symptoms and exacerbation risk.We conducted a 52-week, double-blind, multicenter trial involving patients 12 years of age or older who (...) had mild asthma and were eligible for treatment with regular inhaled glucocorticoids. Patients were randomly assigned to receive twice-daily placebo plus budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed or budesonide maintenance therapy with twice-daily budesonide (200 μg) plus terbutaline (0.5 mg) used as needed. The primary analysis compared budesonide-formoterol used as needed with budesonide maintenance therapy with regard to the annualized rate of severe

2018 NEJM Controlled trial quality: predicted high

20. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. (Abstract)

Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a fast-acting β2-agonist may be an alternative to conventional treatment strategies.We conducted a 52-week, double-blind trial involving patients 12 years of age or older with mild asthma. Patients were randomly assigned to one of three regimens: twice-daily placebo plus terbutaline (0.5 mg) used as needed (terbutaline group), twice-daily placebo plus (...) budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed (budesonide-formoterol group), or twice-daily budesonide (200 μg) plus terbutaline used as needed (budesonide maintenance group). The primary objective was to investigate the superiority of as-needed budesonide-formoterol to as-needed terbutaline with regard to electronically recorded weeks with well-controlled asthma.A total of 3849 patients underwent randomization, and 3836 (1277 in the terbutaline group, 1277

2018 NEJM